8-K: Sangamo Therapeutics Faces Nasdaq Delisting, Reports Q1 2026 Results

Sangamo Therapeutics reported first quarter 2026 financial results, including a net loss of $31.0 million, while also announcing its common stock was delisted from Nasdaq and began trading on the OTCQB Venture Market.

Summary

• Sangamo Therapeutics reported a net loss of $31.0 million ($0.08 per share) for the first quarter ended March 31, 2026, compared to a net loss of $30.6 million ($0.14 per share) in the same period of 2025.
• Revenues for Q1 2026 were $1.4 million, a decrease from $6.4 million in Q1 2025, primarily due to the cessation of revenue from a collaboration agreement with Pfizer.
• Total operating expenses on a GAAP basis were $33.4 million in Q1 2026, down from $36.1 million in Q1 2025, driven by lower personnel and facilities costs.
• The company's cash and cash equivalents stood at $27.6 million as of March 31, 2026, with an estimated sufficiency into the third quarter of 2026.
• Sangamo received a delisting determination from Nasdaq due to non-compliance with minimum bid price requirements and its stock began trading on the OTCQB Venture Market on May 5, 2026, with an appeal hearing scheduled for June 9, 2026.
• The company is advancing its rolling Biologics License Application (BLA) submission for ST-920 for Fabry disease, with preclinical and clinical modules submitted to the FDA.
• Six sites have been activated for the Phase 1/2 STAND study evaluating ST-503 for chronic neuropathic pain.
• Sangamo provided 2026 financial guidance, expecting total operating expenses between $110 million to $130 million on a GAAP basis.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the Nasdaq delisting, reduced revenues, increased net loss, and the critical need for additional funding, despite progress in pipeline development.

Positives

• Advancement of the rolling BLA submission for ST-920 for Fabry disease, with preclinical and clinical modules submitted to the FDA.
• The antibody assay companion diagnostic for ST-920 has been accepted by the FDA for Premarket Approval (PMA).
• FDA has affirmed that two-year eGFR data may serve as confirmatory evidence for traditional approval of ST-920.
• Six sites activated for the Phase 1/2 STAND study evaluating ST-503 for chronic neuropathic pain.
• Productive interaction with the UK MHRA regarding the ST-506 prion disease study.
• Participation in the ASGCT Annual Meeting showcasing pipeline progression and technology advances.
• Increase in cash and cash equivalents to $27.6 million as of March 31, 2026, from $20.9 million at the end of 2025.
• Total operating expenses on a GAAP basis decreased to $33.4 million in Q1 2026 from $36.1 million in Q1 2025.

Negatives

• Received a delisting determination from The Nasdaq Capital Market due to non-compliance with minimum bid price requirements.
• Common stock began trading on the OTCQB Venture Market, a less prominent exchange, on May 5, 2026.
• Revenues decreased significantly to $1.4 million in Q1 2026 from $6.4 million in Q1 2025, largely due to the end of a Pfizer collaboration revenue stream.
• Consolidated net loss for Q1 2026 was $31.0 million, a slight increase from $30.6 million in Q1 2025.
• Estimated cash and cash equivalents are sufficient to fund planned operations only into the third quarter of 2026, highlighting a need for additional funding.
• The company's total stockholders deficit increased to $18.955 million as of March 31, 2026, from $14.268 million as of December 31, 2025.

Risks

• Risk of being unable to secure significant additional funding, which is critical for continued operations and execution of the operating plan, potentially leading to cessation of operations, liquidation, or bankruptcy.
• Potential for collaborators and licensees to breach or terminate agreements.
• Uncertainty and cost of the research and development process, with preclinical results not always indicative of future clinical trial outcomes.
• Impact of macroeconomic factors, geopolitical instability, inflation, and interest rate fluctuations on business operations and clinical trials.
• Clinical trial delays, pauses, or holds could impact timelines and commercialization.
• Uncertainty in clinical trial results, with no guarantee that observed therapeutic effects will be durable or that final data will validate safety and efficacy for regulatory approval.
• The unpredictable regulatory approval process across multiple authorities.
• Reliance on early clinical trial results, which may not be predictive of future trial outcomes.

Future Outlook

Sangamo expects total operating expenses in the range of approximately $110 million to $130 million on a GAAP basis for 2026. The company's cash and cash equivalents are estimated to be sufficient to fund planned operations into the third quarter of 2026, contingent upon securing adequate additional funding. The rolling BLA submission for ST-920 is expected as early as the summer of 2026, subject to funding.

Management Comments

• "During the first quarter, we advanced our rolling BLA submission for ST-920 and continued to progress our differentiated neurology pipeline," said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics.
• "We remain focused on executing against our regulatory and clinical priorities while pursuing opportunities to secure additional funding and support the long-term potential of our pipeline."

Industry Context

StockSavvy.ai notes that Sangamo Therapeutics' situation highlights the significant financial pressures and regulatory hurdles common in the genomic medicine sector, where long development cycles and substantial capital requirements necessitate careful financial management and strategic partnerships. The transition to OTC markets and the ongoing need for funding are critical challenges for companies at this stage of development.

Comparison to Industry Standards

• Companies in the gene therapy space often face similar challenges with Nasdaq listing requirements due to the high burn rate and long path to commercialization.
• The need for substantial additional funding is a recurring theme for many clinical-stage biotechnology firms, impacting their ability to meet operational expenses and pursue regulatory milestones.
• The use of rolling BLA submissions and accelerated approval pathways is becoming more common as regulatory agencies seek to expedite promising therapies for unmet medical needs, as seen with ST-920 for Fabry disease.

Legal Proceedings

• The company is appealing a delisting determination from The Nasdaq Capital Market.

Stakeholder Impact

• Shareholders: Potential negative impact due to delisting from Nasdaq, transition to OTCQB, and the ongoing financial challenges and uncertainty surrounding future funding and operations.
• Employees: Potential impact from cost reduction measures and the overall financial health of the company.
• Creditors: Increased risk due to the company's limited cash runway and potential need for bankruptcy protection if funding is not secured.

Next Steps

• Appeal the Nasdaq delisting determination at a hearing scheduled for June 9, 2026.
• Continue the rolling BLA submission for ST-920 to the FDA, with completion expected as early as summer 2026, subject to funding.
• Seek Premarket Approval (PMA) for the antibody assay companion diagnostic for ST-920.
• Continue clinical development of ST-503 for chronic neuropathic pain.
• Advance Clinical Trial Application (CTA) enabling activities for ST-506 for prion disease.
• Secure additional funding to support operations and pipeline development.
• Pursue a potential Fabry commercialization agreement.

Key Dates

Recommendation

While the company shows progress in its pipeline, the immediate concerns of Nasdaq delisting, reduced revenue, increased net loss, and critical need for funding warrant a cautious 'hold' recommendation. Investors should monitor the outcome of the Nasdaq appeal and the company's ability to secure necessary financing before considering a more aggressive stance.

Keywords

Sangamo Therapeutics, Genomic Medicine, Fabry Disease, ST-920, Gene Therapy, Neuropathic Pain, ST-503, Nasdaq Delisting